Data law adds to cost & time of clinical trials, says ACRO

By Nick Taylor

- Last updated on GMT

Related tags: Medicine, Health care, Acro

ACRO has spoken in support of IMS Health amid concerns restrictions on prescriber identifiable (PI) data could hinder research.

IMS’ five-year fight to keep PI data accessible has now reached the US Supreme Court. A number of groups, including the Association of Clinical Research Organizations (ACRO), have raised concerns about the impact PI data restrictions would have on clinical research.

It would be more difficult to design clinical trials to test new medicines, identify doctors to participate in clinical trials, recruit patients who would most likely benefit from a new treatment, and compare the efficacy of new medicines to those already on the market​”, said ACRO​.

However, some want to restrict PI data use. IMS has fought a series of court cases to overturn PI data availability legislation passed in New Hampshire, Vermont and Maine. The Vermont law has been upheld by one court, overturned by another, and is now before the US Supreme Court.

Vermont doctors pressed for this law because of their concerns about privacy and because they view this data mining practice as an intrusion into the way doctors practice medicine​”, said William Sorrell, Vermont attorney general.

Doug Peddicord, executive director of ACRO, said: “To be clear, the data in question in the IMS case meets the standards of HIPAA (Health Insurance Portability and Accountability Act)​ and is not ‘personally identifiable health information’ so privacy is not the issue here​.”

“A disturbing trend”

Vermont is just one small US State but its PI data law, coupled to moves in Maine, New Hampshire, and other locations, is, according to ACRO, part of a shift towards “overreaching restrictions​”.

In response ACRO has spoken out against further restrictions on de-identified data. “We see a disturbing trend toward unnecessary restrictions being placed on the use of medical data, which can result in making research more time-consuming and expensive​”, said Peddicord.

The Vermont law makes an exception for data used in research. However, ACRO fears “the restriction on the use of the data for marketing will severely curtail the economic incentive to gather the data in the first instance​”.

Oral arguments in the case, Sorrell v IMS Health​, will be heard on April 26. ACRO has filed an amicus curiae​, or friend of court, brief in support of IMS. A ruling is expected in June 2011. The Biotechnology Industry Organization (BIO) has also filed a brief​ in support of IMS.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars